{'fraction_non_alphanumeric': 0.03021978021978022, 'fraction_numerical': 0.00641025641025641, 'mean_word_length': 5.664634146341464, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The epstein‐barr‐virus‐encoded membrane protein LMP but not the nuclear antigen EBNA‐1 induces rejection of transfected murine mammary carcinoma cells

The EBV‐encoded membrane protein (LMP) and the nuclear antigen EBNA‐I were compared for their capacity to induce rejection of transfected murine mammary carcinoma cells in syngenelc hosts. The tumorigenic potential of stable LMP and EBNA‐I expressing sublines of the ACA (H‐2f)‐derived mammary carcinoma line S6C was tested in pre‐immunized syngeneic and semi‐syngeneic animals. LMP expressing S6C cells elicited a strong rejection response as demonstrated by the lower tumor take and slower growth in immunized vs. control mice. In contrast, EBNA‐I‐expressing cells were non‐immunogenic in syngeneic hosts and in one semi‐syngeneic F1‐hybrid. Rejection in 2 additional F1‐hybrids did not appear to be due to EBNA‐I‐specific immune responses. Our findings support the hypothesis that the escape of EBV carrying tumor cells from EBV‐specific immune surveillance may be facilitated by the fact that viral gene expression is limited to EBNA‐I.